Literature DB >> 33554313

Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer.

Wenqian Zheng1,2, Jinhui Hu1,2, Yiming Lv1,2, Bingjun Bai1,2, Lina Shan1,2, Kangke Chen2, Sheng Dai1,2, Hongbo Zhu3,4.   

Abstract

The use of the anthelmintic drug pyrvinium pamoate (PP) in cancer therapy has been extensively investigated in the last decade. PP has been shown to have an inhibitory effect in colorectal cancer (CRC), but the underlying mechanism remains elusive. We aimed to investigate the antitumor activity and mechanisms of PP in CRC. In the present study, we used CCK-8 assays, colony formation assays, and western blotting to reveal that PP effectively suppressed CRC cell proliferation and the AKT-dependent signaling pathway in a concentration-dependent and time-dependent manner. Flow cytometric analysis and fluorescence microscopy demonstrated that PP increased intracellular reactive oxygen species (ROS) accumulation. We found that the inhibitory effect of PP on cell proliferation and AKT protein expression induced by PP could be partially reversed by N-acetyl-L-cysteine (NAC), an ROS scavenger. In addition, the results also demonstrated that PP inhibited cell migration by modulating epithelial-to-mesenchymal transition (EMT)-related proteins, including E-cadherin and vimentin. In conclusion, our data suggested that PP effectively inhibited cell proliferation through the ROS-mediated AKT-dependent signaling pathway in CRC, further providing evidence for the use of PP as an antitumor agent.

Entities:  

Keywords:  AKT pathway; CRC; Cell migration; Pyrvinium; ROS

Year:  2021        PMID: 33554313     DOI: 10.1007/s12032-021-01472-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  35 in total

Review 1.  Colorectal cancer.

Authors:  Evelien Dekker; Pieter J Tanis; Jasper L A Vleugels; Pashtoon M Kasi; Michael B Wallace
Journal:  Lancet       Date:  2019-10-19       Impact factor: 79.321

Review 2.  ROS signalling in the biology of cancer.

Authors:  Jennifer N Moloney; Thomas G Cotter
Journal:  Semin Cell Dev Biol       Date:  2017-06-03       Impact factor: 7.727

3.  Adolescent and young adult oncology-past, present, and future.

Authors:  Allison G Close; Alexandra Dreyzin; Kimberly D Miller; Brittani K N Seynnaeve; Louis B Rapkin
Journal:  CA Cancer J Clin       Date:  2019-10-08       Impact factor: 508.702

Review 4.  Targeted therapies: a new generation of cancer treatments.

Authors:  David E Gerber
Journal:  Am Fam Physician       Date:  2008-02-01       Impact factor: 3.292

Review 5.  Mitochondrial formation of reactive oxygen species.

Authors:  Julio F Turrens
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

Review 6.  ROS stress in cancer cells and therapeutic implications.

Authors:  Helene Pelicano; Dennis Carney; Peng Huang
Journal:  Drug Resist Updat       Date:  2004-04       Impact factor: 18.500

Review 7.  Reactive oxygen species, cellular redox systems, and apoptosis.

Authors:  Magdalena L Circu; Tak Yee Aw
Journal:  Free Radic Biol Med       Date:  2010-01-04       Impact factor: 7.376

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Antitumor activity and systemic effects of PVM/MA-shelled selol nanocapsules in lung adenocarcinoma-bearing mice.

Authors:  Ludmilla Regina de Souza; Luis Alexandre Muehlmann; Lívia Carneiro Matos; Rosana Simón-Vázquez; Zulmira Guerreiro Marques Lacava; Alfredo Maurício Batista De-Paula; Ewa Mosiniewicz-Szablewska; Piotr Suchocki; Paulo César Morais; África González-Fernández; Sônia Nair Báo; Ricardo Bentes Azevedo
Journal:  Nanotechnology       Date:  2015-11-18       Impact factor: 3.874

Review 10.  Chemotherapy induced DNA damage response: convergence of drugs and pathways.

Authors:  Derek Woods; John J Turchi
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.